Gene

CBLC

Cbl proto-oncogene C

Explore in graph →CI-GENE-00032442HGNC:15961 ENSG00000142273 NCBI 23624 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CBLC EXPRESSION1
Olaparib	Breast Carcinoma	Predictive	D	Supports Resistance	2	accepted	EID805 The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro in two breast carcinoma cell lines (MCF7 and HS578T). I… (full text at CIViC) PMID 25883215 · Frankum et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (3)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Metastatic Melanoma (MSK, JCO Precis Oncol 2017) skcm_vanderbilt_mskcc_2015	Cutaneous Melanoma	Ssm	2	11

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
· Oncotarget · 2015 · PMID 25883215 · validated civic_curation pubmed